Researchers show that Plasmodium falciparum glutamic-acid-rich protein (PfGARP), a 80 kDa antigen expressed on the surface of P. falciparum-infected erythrocytes, is a malaria vaccine candidate for specifically targeting the blood stage of this parasite.